Expedited drug review process: Fast, but flawed
Open Access
- 1 June 2016
- journal article
- editorial
- Published by SAGE Publications in Journal of Pharmacology and Pharmacotherapeutics
- Vol. 7 (2) , 57-61
Abstract
J Pharmacol Pharmacother, Official publication of InPharm Association, IndiaKeywords
This publication has 11 references indexed in Scilit:
- Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort studyBMJ, 2015
- Ponatinib: Accelerated DisapprovalThe Oncologist, 2015
- Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials.2015
- Cutaneous Epithelial Tumors Induced by Vemurafenib Involve the MAPK and Pi3KCA Pathways but Not HPV nor HPyV Viral InfectionPLOS ONE, 2014
- Cangrelor infusion is associated with an increased risk for bleeding: Meta-analysis of randomized trialsInternational Journal of Cardiology, 2013
- No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-AnalysisPLOS ONE, 2012
- Understanding noninferiority trialsKorean Journal of Pediatrics, 2012
- Through the looking glass: understanding non-inferiorityTrials, 2011
- Health-related quality of life and cancer clinical trialsTherapeutic Advances in Medical Oncology, 2011
- Surrogate End Points in Clinical Research: Hazardous to Your HealthObstetrics & Gynecology, 2005